Leveraging Childhood Vaccination Recall to Fight Cancer with Chris Bradley Loki Therapeutics TRANSCRIPT
Download PDFSep 2, 2020
Chris Bradley, CEO and Co-Founder, Loki Therapeutics talks about a new generation of cancer immune therapy that takes advantage of the body's ability to fight antigens it already recognizes from a previous childhood vaccination. The delivery mechanism uses an attenuated bacteria listeria monocytogenes that colonizes the...
Sep 2, 2020
Chris Bradley, CEO and Co-Founder, Loki Therapeutics talks about a new generation of cancer immune therapy that takes advantage of the body's ability to fight antigens it already recognizes from a previous childhood vaccination. The delivery mechanism uses an attenuated bacteria listeria monocytogenes that colonizes the...
Treating Myelodysplastic Syndrome by Downregulating the RAS Pathway with Dr. Steven Fruchtman Onconova Therapeutics TRANSCRIPT
Download PDFJul 20, 2020
Steven M. Fruchtman, M.D., President and Chief Executive Officer, Onconova Therapeutics discusses Rigosertib, a drug that has the potential to downregulate the RAS pathway, the most commonly mutated gene in cancer. Rigosertib is a proprietary phase 3 small molecule, currently being evaluated in second-line treatment of...
Jul 20, 2020
Steven M. Fruchtman, M.D., President and Chief Executive Officer, Onconova Therapeutics discusses Rigosertib, a drug that has the potential to downregulate the RAS pathway, the most commonly mutated gene in cancer. Rigosertib is a proprietary phase 3 small molecule, currently being evaluated in second-line treatment of...
Advances in Targeted Cancer Therapy with Dr. Edith Perez Bolt Biotherapeutics TRANSCRIPT
Download PDFJun 25, 2020
Dr. Edith Perez, Chief Medical Officer, Bolt Biotherapeutics discusses an innovative new platform for the treatment of patients with cancer. The Boltbody™ platform uses a combination of tumor targeting antibodies and localized stimulation of the immune system, or immune stimulating antibody conjugates, to fight...